Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.06), $0.04 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Barclays Upgrades United Internet AG (UTDI:GR) (UDIRY) to Overweight
• Nomura/Instinet Resumes Toyota Tsusho Corp (8015:JP) at Buy